Search

Your search keyword '"Philip C. Schouten"' showing total 3 results
Start Over Author "Philip C. Schouten" Journal clinical cancer research : an official journal of the american association for cancer research
3 results on '"Philip C. Schouten"'

1. Ovarian Cancer-Specific

Author

Philip C, Schouten, Lisa, Richters, Daniel J, Vis, Stefan, Kommoss, Ewald, van Dijk, Corinna, Ernst, Roelof J C, Kluin, Frederik, Marmé, Esther H, Lips, Sandra, Schmidt, Esther, Scheerman, Katharina, Prieske, Carolien H M, van Deurzen, Alexander, Burges, Patricia C, Ewing-Graham, Dimo, Dietrich, Agnes, Jager, Nikolaus, de Gregorio, Jan, Hauke, Andreas, du Bois, Petra M, Nederlof, Lodewyk F, Wessels, Eric, Hahnen, Philipp, Harter, Sabine C, Linn, and Rita K, Schmutzler

Subjects
BRCA2 Protein, Ovarian Neoplasms, BRCA1 Protein, Genes, BRCA2, Mutation, Humans, Breast Neoplasms, Female, Homologous Recombination, Germ-Line Mutation
Abstract

Previously, we developed breast cancerThe detection rate of theThe newly trained classifiers detected most

Published
2021

2. EZH2 Is Overexpressed in

Author

Julian, Puppe, Mark, Opdam, Philip C, Schouten, Katarzyna, Jóźwiak, Esther, Lips, Tesa, Severson, Marieke, van de Ven, Chiara, Brambillasca, Peter, Bouwman, Olaf, van Tellingen, René, Bernards, Jelle, Wesseling, Christian, Eichler, Fabinshy, Thangarajah, Wolfram, Malter, Gaurav Kumar, Pandey, Luka, Ozretić, Carlos, Caldas, Maarten, van Lohuizen, Michael, Hauptmann, Kerstin, Rhiem, Eric, Hahnen, H Christian, Reinhardt, Reinhard, Büttner, Peter, Mallmann, Birgid, Schömig-Markiefka, Rita, Schmutzler, Sabine, Linn, and Jos, Jonkers

Subjects
BRCA2 Protein, Mice, Knockout, BRCA1 Protein, Antineoplastic Agents, Breast Neoplasms, Mammary Neoplasms, Animal, Survival Rate, Mice, Treatment Outcome, Biomarkers, Tumor, Animals, Humans, Enhancer of Zeste Homolog 2 Protein, Female, Platinum
Abstract

BRCA1-deficient breast cancers carry a specific DNA copy-number signature ("EZH2 expression was analyzed in 497 breast cancers using IHC or RNA sequencing. We classified 370 tumors by copy-number profiles asThe highest EZH2 expression was found in BRCA1-associated tumors harboring aOur findings demonstrate that EZH2 is expressed at significantly higher levels in

Published
2018

3. Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

Author

Yannick Boursin, Matty Meijers, Remi A. Nout, Marthe M de Jonge, Bastien Job, Aurélie Auguste, Etienne Rouleau, David N. Church, Vincent T.H.B.M. Smit, Tjalling Bosse, Mark A. Glaire, Harry Vrieling, Philip C. Schouten, Maaike P.G. Vreeswijk, Alexandra Leary, Natalja T. ter Haar, Cornelis D. de Kroon, and Lise M van Wijk

Subjects
0301 basic medicine, Cancer Research, endocrine system diseases, Somatic cell, RAD51, Poly(ADP-ribose) Polymerase Inhibitors, 03 medical and health sciences, Endometrium, 0302 clinical medicine, Medicine, Humans, DNA Breaks, Double-Stranded, Prospective Studies, Prospective cohort study, Homologous Recombination, Gene, Aged, BRCA2 Protein, Comparative Genomic Hybridization, business.industry, BRCA1 Protein, Endometrial cancer, High-Throughput Nucleotide Sequencing, Histology, Middle Aged, medicine.disease, 3. Good health, Endometrial Neoplasms, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Cancer research, Female, Rad51 Recombinase, Neoplasm Grading, business, Comparative genomic hybridization, SNP array
Abstract

Purpose: The elevated levels of somatic copy-number alterations (SCNAs) in a subset of high-risk endometrial cancers are suggestive of defects in pathways governing genome integrity. We sought to assess the prevalence of homologous recombination deficiency (HRD) in endometrial cancers and its association with histopathologic and molecular characteristics. Experimental Design: Fresh tumor tissue was prospectively collected from 36 endometrial cancers, and functional HRD was examined by the ability of replicating tumor cells to accumulate RAD51 protein at DNA double-strand breaks (RAD51 foci) induced by ionizing radiation. Genomic alterations were determined by next-generation sequencing and array comparative genomic hybridization/SNP array. The prevalence of BRCA-associated genomic scars, a surrogate marker for HRD, was determined in the The Cancer Genome Atlas (TCGA) endometrial cancer cohort. Results: Most endometrial cancers included in the final analysis (n = 25) were of non-endometrioid (52%), grade 3 (60%) histology, and FIGO stage I (72%). HRD was observed in 24% (n = 6) of cases and was restricted to non-endometrioid endometrial cancers (NEEC), with 46% of NEECs being HRD compared with none of the endometrioid endometrial cancers (EEC, P = 0.014). All but 1 of the HRD cases harbored either a pathogenic BRCA1 variant or high somatic copy-number (SCN) losses of HR genes. Analysis of TCGA cases supported these results, with BRCA-associated genomic scars present in up to 48% (63/132) of NEEC versus 12% (37/312) of EEC (P < 0.001). Conclusions: HRD occurs in endometrial cancers and is largely restricted to non-endometrioid, TP53-mutant endometrial cancers. Evaluation of HRD may help select patients that could benefit from treatments targeting this defect, including platinum compounds and PARP inhibitors.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results